Laboratory investigations in the diagnosis and follow-up of GH-related disorders
Archives of Endocrinology and Metabolism, 2020 In addition to auxiological, clinical and metabolic features measurements of growth hormone (GH) and insulin-like growth factor I (IGF-I) complement our tools in diagnosis and follow-up of GH-related disorders.
Katharina Schilbach, Martin Bidlingmaier
doaj +1 more source
Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess [PDF]
, 2017 The interplay between vitamin D and the growth hormone (GH)/insulin-like growth factor (IGF)-I system is very complex and to date it is not fully understood.
Ciresi, A., Giordano, C.
core +1 more source
Journal of Clinical Endocrinology and Metabolism, 2019 INTRODUCTION Pegvisomant (PEG) in monotherapy or combined with somatostatin analogs (SSAs) is used to control acromegaly, improving metabolism. However, the metabolic changes induced by PEG have not been systematically reviewed.
T. Feola +9 more
semanticscholar +1 more source
A retrospective multicenter study of pegvisomant use in acromegaly within Russian Federation
Ожирение и метаболизмBACKGROUND: Acromegaly is a chronic neuroendocrine disorder, the prognosis of which depends on timely and adequate treatment. A high percentage of non-radical surgical treatment and the problem of resistance to first-line drug therapy necessitate the ...
E. G. Przhyalkovskaya +12 more
doaj +1 more source
Treatment update on acromegaly [PDF]
Einstein (São Paulo), 2004 Pegvisomant is a new drug that blocks growth hormone peripheralreceptors, allowing normalization of insulin-like growth factor-1levels and consequently of clinical symptoms, reducing morbidityand mortality associated with acromegaly in almost all ...
Tatiana Hotimsky Millner +1 more
doaj
International Journal of Endocrinology, 2012 This paper outlines the present status of medical therapy of acromegaly. Indications for permanent postoperative treatment, postirradiation treamtent to bridge the interval until remission as well as primary medical therapy are elaborated.
U. Plöckinger
doaj +1 more source
The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets [PDF]
, 2014 Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. Different signalling pathways have been identified to be implicated in the pathogenesis of HCC; among these, GH, IGF and somatostatin (SST) pathways have emerged as some of the
Annamaria Colao +7 more
core +1 more source
Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment
Frontiers in Endocrinology, 2018 Acromegaly is a rare disease due to chronic GH excess and to the consequent increase in IGF-1 levels. Both GH and IGF-1 play a role in intermediate metabolism affecting glucose homeostasis. Indeed, chronic GH excess impairs insulin sensitivity, increases
Francesco Ferraù +4 more
doaj +1 more source
Tumorgenezis és a szomatosztatin hatásmechanizmusának vizsgálata humán hipofízis adenomákban = Tumorigenesis and the effects of somatostatin in human pituitary adenomas [PDF]
, 2012 Protein western array módszerrel vizsgáltuk ép és tumoros hypophysis mintákból a fehérjeexpressziót. Humán hypophysis szövetben korábban nem ismert 116 fehérjét detektáltunk, továbbá a hypophysis tumogenezisében feltételezhetően szerepet játszó ...
Góth, Miklós +5 more
core
Elevated intraocular pressure in patients with acromegaly [PDF]
, 2014 To evaluate central corneal thickness (CCT) and intraocular pressure (IOP) in a cohort of acromegalic patients, and to correlate CCT with serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1)
Floriani, Irene +7 more
core +1 more source